Persistent URL of this record https://hdl.handle.net/1887/65995
Documents
-
- Download
- Titlte Pages_Contents
- open access
-
- Download
- Part I: Chapter 2
- open access
-
- Download
- Part II: Chapter 3
- open access
- Full text at publishers site
-
- Download
- Part II: Chapter 4
- open access
- Full text at publishers site
-
- Download
- Part II: Chapter 5
- open access
- Full text at publishers site
-
- Download
- Part III: Chapter 6
- open access
- Full text at publishers site
-
- Download
- Part III: Chapter 7
- open access
-
- Download
- Part III: Chapter 8
- open access
- Full text at publishers site
-
- Download
- Chapter 9: Summary in English
- open access
-
- Download
- Chapter 10: Summary in Dutch
- open access
-
- Download
- Propositions
- open access
In Collections
This item can be found in the following collections:
Predicting outcome after liver transplantation
in liver transplantation was investigated. These models can be used for multiple purposes,
including risk indication, outcome prediction and benchmarking between transplant centers.
As such, several steps have been made towards evidence-based liver allocation and proper
selection of liver allografts in times of organ shortage and the current system of severitybased
liver allocation (by MELD the score). Further refinement of these models is necessary
in order to optimize donor to recipient matching and achieve an objective, transparent and
well-informed system of liver allocation. Altogether, the efforts made here to improve waitlist
and transplantation outcomes, are meant for the individual transplant candidate on the liver
transplant waitlist and as a whole, for the transplant community.
- All authors
- Blok, J.J.
- Supervisor
- Hamming, J.F.
- Co-supervisor
- Braat, A.E.
- Committee
- Alwayn, I.P.J.; Coenraad, M.J.; Hoek, B. van; Metselaar, H.J.; Porte, R.J.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
- Date
- 2018-09-18
- ISBN (print)
- 9789463611251
Funding
- Sponsorship
- Astellas Pharma, Chiesie Pharmaceuticals, NTV, Bridge to Life, Chipsoft